The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis

• Published in: Journal of Psoriasis and Psoriatic Arthritis 2023-07, Vol.8 (3), p.107-117
• Main Authors: Shi, Zhen-Rui, Mabuchi, Tomotaka, Riutta, Sarah J., Wu, Xuesong, Peterson, Francis C., Volkman, Brian F., Hwang, Sam T.
• Format: Article
• Language: English
• Subjects: Reviews
• ISSN: 2475-5303; 2475-5311; 2475-5311
• DOI: 10.1177/24755303231159106

Background Chemokines represent a superfamily of immune-modulatory small protein molecules that regulate leukocyte migration to inflammatory sites through their chemoattractant and cell signaling properties. This review focuses on the immunological functions of the CCR6 chemokine receptor and is chemokine ligand, CCL20, that contribute to it role in inflammation in human psoriasis. Methods Peer-reviewed relevant articles are searched and selected from 2000 to 2022 using the search engines including PubMed and Google Scholar. Results After selectively reviewing and evaluating over seventy articles, a comprehensive overview on the immunology of CCL20-CCR6 axis in psoriasis and psoriatic arthritis, the X-ray crystal structures of CCL20 monomers, and the potential of developing clinical therapies targeting this axis is summarized. Conclusions Over the past decade, preclinical studies carried out in animal models of psoriasis involving agents targeting CCL20-CCR6 axis have yielded promising results. Other studies that this axis may play a role in a number of other autoimmune diseases, including rheumatoid arthritis, suggesting a rationale for further investigation into this key signaling/migratory pathway.